Home / Guides / US peptide rules 2026
Legal guide

7 US Peptide Rules Every Researcher Should Know in 2026

Published 22 November 2026 · For laboratory research and education only
Research use only · Not medical advice
7 US peptide rules for 2026

Seven rules that decide what is and is not allowed with peptides in the United States in 2026, from FDA approval and research-use-only labels to the October HHS compounding policy. Each rule links to the official record. This is a summary for researchers, not legal advice. Checked 22 November 2026.

1. Research peptides are not FDA-approved drugs

None of the popular research peptides, from BPC-157 to retatrutide, is an FDA-approved medicine. Selling them for use in people is selling an unapproved drug. Details: are peptides legal?

2. A “research use only” label is not a shield

FDA judges what a product is for from the whole website. Its 2026 warning letters cited dosing guides, peptide calculators sold next to bacteriostatic water, health claims and GLP-1 code names such as “GLP-3 Reta”. The five letters of 24 August 2026 rejected research-use labels as cover.

3. Only licensed 503A pharmacies are covered by the HHS policy

On 30 October 2026 HHS published an interim enforcement discretion policy (91 FR 68526) for six peptides: BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c. It covers state-licensed pharmacies, federal facilities and licensed physicians compounding under section 503A, with an FDA-registered source, a full COA and one peptide per product. It does not cover research-use-only sales. Explained: the HHS peptide policy.

4. The July 2026 FDA vote was advice, not approval

FDA’s Pharmacy Compounding Advisory Committee recommended the same six peptides for the 503A bulks list on 23 to 24 July 2026 and voted against DSIP. FDA staff had recommended against all seven. Formal rulemaking must follow, which commentators estimate at 6 to 18 months. More: FDA peptide vote.

5. GLP-1 research products draw the most enforcement

Semaglutide, tirzepatide and retatrutide appear in most FDA letters to research-peptide sellers, and Eli Lilly filed civil suits against research-retatrutide sellers in August 2026. None of the six-peptide relief applies to them.

6. Check every seller against the FDA warning letter list

Our tracker lists 17 letters from February 2024 to August 2026, from SwissChems to Peptide Partners. A supplier with a letter on file is never listed on this site. Tracker: FDA peptide warning letters.

7. Weak enforcement does not mean quality is checked

Public Citizen’s 19 November 2026 report argues FDA enforcement on unapproved peptides largely stopped in 2025. If nobody checks the market, the lab has to: lot-matched COAs, mass-spec identity and measured content. Report summary: Public Citizen on FDA peptide enforcement. Checklist: verify a peptide COA.

Timeline: US peptide rules, 2024 to 2026

DateEvent
Feb 2024First FDA letters to research-peptide sellers (US Chem Labs, Helix Chemical Supply)
Dec 2024Letters to Prime Peptides, Summit Research Peptides and SwissChems
31 Mar 2026Five more letters, including Prime Sciences and Gram Peptides
15 Apr 2026BPC-157 and Epitalon removed from FDA’s Category 2 bulks list after nominations were withdrawn
23–24 Jul 2026FDA advisory committee recommends six peptides for the 503A bulks list
24 Aug 2026Five warning letters reject “research use only” labels
30 Oct 2026HHS interim 503A policy published (91 FR 68526)
13 Nov 2026Comment period on the HHS policy closes
19 Nov 2026Public Citizen report on FDA enforcement

Choosing a lab supplier: top 10 peptide vendors in the USA · how we verify suppliers.

Frequently asked questions

Buying a research chemical for laboratory research is not the issue regulators target. Selling or using unapproved peptides for people is: none of the popular research peptides is FDA-approved, and FDA has said a research-use-only label does not protect a seller whose site shows human use.

HHS said it will not take enforcement action against licensed 503A pharmacies that compound BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c under strict conditions (Federal Register, 30 October 2026, 91 FR 68526). It is interim, it is not FDA approval and it does not cover research-use-only products.

No. In July 2026 an FDA advisory committee narrowly recommended BPC-157 and five other peptides for the 503A bulks list. That vote is advice only; FDA rulemaking must follow.

Our tracker lists 17 letters to research-peptide sellers from February 2024 to August 2026, including five on 24 August 2026. GLP-1 compounds appear in most of them.

Every peptide outside the six, including GHK-Cu, Selank, DSIP, retatrutide and tirzepatide research products, and all blends.

Deal of the week50% off research peptides

Code IZBA50OFF at Ascension Peptides (US).

Get 50% off now →See all codes and pricesAd · affiliate link · Research use only

Free PDF: November peptide codes + price-per-mg sheet

All 15 supplier codes and the lowest price per mg for 14 research compounds, on 2 pages. Updated monthly. For laboratory research use only.

No spam. Unsubscribe any time. Read our privacy policy.

Managed by Teeztech Agency